About Neuroptika
Neuroptika is a Healthcare company based in Cambridge (United States) founded in 2018 by Chiho Fukiage. Regenerative treatments for ophthalmic diseases are discovered and developed. Neuroptika has raised $3 million across 1 funding round from investors including KB Investment. Its chief executive, as recorded, is Hyunsuk Tim Min. Neuroptika offers products and services including NRO-1, NRO-CMK, NRO-VTN, and Undisclosed Therapy. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its legal entity is Neuroptika Inc. Its competitors include Annexon, Aldeyra and Gyroscope; 2 of its 3 listed competitors have raised funding.
Company details
Neuroptika was founded in 2018 and is based in Cambridge, United States. Operations focus on the biotechnology sector, specifically the discovery and development of regenerative therapies for ophthalmic conditions. The NRO-1 technology, a topically delivered nerve regenerative therapy, has completed a phase 1 clinical study and demonstrated neuron regeneration in nonclinical studies. Leadership includes co-founder Chiho Fukiage and CEO Hyunsuk Tim Min.
- Headquarters Cambridge, United States
- Founders Chiho Fukiage
- SectorsHealthcare
- Email••••••••
- Website neuroptika.com
- Social LinkedIn
- Legal Name Neuroptika Inc.
- Total Equity Funding$3M (USD)
in 1 rounds
- Latest Funding Round$3M (USD), Series A
Jan 2019
- Investors
Products & Services of Neuroptika
Neuroptika offers a comprehensive portfolio of products and services, including NRO-1, NRO-CMK, NRO-VTN, and Undisclosed Therapy.
Regenerates corneal nerves for dry eye disease treatment
Protects retinal cells for glaucoma management
Inhibits drusen to treat dry age-related macular degeneration
Targets diabetic retinopathy and related eye conditions
Funding Insights of Neuroptika
Neuroptika has successfully raised a total of $3M through 1 strategic funding round. The most recent funding activity was a Series A round of $3 million completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3M
- Total Rounds 1
- Last Round Series A — $3M
- First Round $3M
(Jan 2019)
- Investors Count 1
All 1 funding rounds of Neuroptika with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2019 | $3M | Series A | – | – |
1 investors in total: 1 institutional.
Investors in Neuroptika
Neuroptika has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include KB Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund investing in early-stage tech startups | 1990 | kbic.co.kr | Seoul, South Korea |
Investor details for Neuroptika
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neuroptika
2 people are tracked at Neuroptika (2 in leadership).
| Name | Role | Group |
|---|---|---|
Chiho Fukiage | Co-Founder | Leadership |
Hyunsuk Tim Min | CEO | Leadership |
Complete people profiles for Neuroptika
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Neuroptika
2 dated milestones of Neuroptika across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Neuroptika is founded.
- Funding First funding round of $3.0M.
Competitors of Neuroptika
Neuroptika has 3 listed competitors in our database, 2 of them funded. They include Annexon, Aldeyra and Gyroscope.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. | |
| gyroscope.cc | 2016 | San Francisco, United States | Mobile SDK developed for app engagement and monetization strategies. |
Detailed competitors of Neuroptika
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Neuroptika (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neuroptika
Complete news archive for Neuroptika
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neuroptika
Neuroptika was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Neuroptika is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Hyunsuk Tim Min is the CEO of Neuroptika, as recorded in our data.
Neuroptika is a funded company, having raised a total of $3M across 1 funding round to date. The company's 1st funding round was a Series A of $3M, raised on Jan 2019.
Neuroptika was founded in 2018 and is based in Cambridge, United States. Operations focus on the biotechnology sector, specifically the discovery and development of regenerative therapies for ophthalmic conditions. The NRO-1 technology, a topically delivered nerve regenerative therapy, has completed a phase 1 clinical study and demonstrated neuron regeneration in nonclinical studies. Leadership includes co-founder Chiho Fukiage and CEO Hyunsuk Tim Min.
Neuroptika offers NRO-1, NRO-CMK, NRO-VTN, and Undisclosed Therapy.
Neuroptika has 1 investor. Key investors include KB Investment.
Neuroptika operates through Neuroptika Inc..